150 results on '"Murati, Anne"'
Search Results
2. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
3. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation
4. CALR‐mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.
5. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms
6. Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis
7. Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients
8. The role of Ikaros in human erythroid differentiation
9. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia
10. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations
11. Gains of EPOR and ERG genes in adult erythroleukaemia
12. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
13. Variant MYST4-CBP gene fusion in a t(10;16) acute myeloid leukaemia
14. Myeloid malignancies: mutations, models and management
15. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
16. Sequential mutational evaluation of CALR ‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression
17. Targeted molecular characterization shows differences between primary and secondary myelofibrosis
18. Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution
19. Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis
20. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
21. Sequential mutational evaluation of CALR ‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.
22. Targeted molecular characterization shows differences between primary and secondary myelofibrosis.
23. Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms
24. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms
25. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1mutations: a FIM study
26. Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome‐wide clonal evolution.
27. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases
28. Syndrome myéloprolifératif avec polyglobulie et translocation t(6;8)(q27;p11) : cas clinique et revue de la littérature
29. Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53Mutation
30. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
31. Incidence of Atrx Mutations in Myelodysplastic Syndromes (MDS)
32. Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution
33. Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients
34. Carcinomatous Myelitis and Meningitis after a Squamous Cell Carcinoma of the Lip
35. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/ NRG1 gene
36. Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110–FGFR1 fusion: Report of a new case and review of the literature
37. Myeloproliferative neoplasm with polycythemia and translocation t(6;8): case report and review of the literature
38. Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms
39. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms
40. Alteration of cohesin genes in myeloid diseases
41. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
42. Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder
43. Familial Malignant Hematological Disorders: A Systematic Assessment in 216 Consecutive Patients with Acute Leukaemia.
44. Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion
45. NACA is a positive regulator of human erythroid-cell differentiation
46. A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion
47. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene
48. Reciprocal translocations in breast tumor cell lines: Cloning of a t(3;20) that targets the FHIT gene
49. Combined mutations of ASXL1, CBL, FLT3, IDH1,IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 andWT1 genes in myelodysplastic syndromes andacute myeloid leukemias.
50. Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.